A Study to Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis (NCT07489885)

🧪 Interventions in This Study

• D-2570 Tablet (DRUG)
• Placebo Tablets (DRUG)

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (20 Sites)

• Study Center — Birmingham, Alabama
• Study Center — Phoenix, Arizona
• Study Center — Chula Vista, California
• Study Center — Fountain Valley, California
• Study Center — Fremont, California
• Study Center — Los Angeles, California
• Study Center — Los Angeles, California
• Study Center — San Diego, California
• Study Center — Fort Lauderdale, Florida
• Study Center — Miramar, Florida
• Study Center — Ocala, Florida
• Study Center — Tampa, Florida
• Study Center — Sandy Springs, Georgia
• Study Center — Savannah, Georgia
• Study Center — Idaho Falls, Idaho
• Study Center — Clarksville, Indiana
• Study Center — Louisville, Kentucky
• Study Center — Mayfield Heights, Ohio
• Study Center — Philadelphia, Pennsylvania
• Study Center — San Antonio, Texas

📞 Contact the Study Coordinator

Phone: (302) 519-5966

Email: kathryn.stazzone@inventisbio.com

Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.

💰 Cost, Insurance & Patient Rights

• 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
• Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
• Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Psoriasis

• Deucravacitinib Adherence Study — Winston-Salem, North Carolina
• An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects — San Diego, California
• Psoriasis Longitudinal Assessment and Registry — Birmingham, Alabama
• Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participation in Study M19-977 — Birmingham, Alabama
• Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With Psoriasis — Birmingham, Alabama
• Prevention of Cardiovascular Disease and Mortality in Patients With Psoriasis or Psoriatic Arthritis — Scottsdale, Arizona

Explore by condition: All Psoriasis clinical trials

💡 How to Participate

1. Check the checklist above to see if you may qualify.
2. Contact the study coordinator using the phone/email above.
3. Ask about the visit schedule, what is covered at no cost, and any travel support.
4. Confirm with your own doctor before making a decision.